Publications by authors named "Fabio Cataldi"

Claim this Profile
A
A population-based survey of beliefs about neck pain and its associated disorders: a cross-sectional study.
Mirella Forte, Federica Nasti, Stefano Schiavone, Matteo Cioeta, Graziana Lullo, Fabio Cataldi

BMC Musculoskelet Disord· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trial.
Evan S Dellon, Margaret H Collins, Albert J Bredenoord, Hamish Philpott, Luc Biedermann, Fabio Cataldi

Lancet Gastroenterol Hepatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study.
Bram Verstockt, Severine Vermeire, Laurent Peyrin-Biroulet, Rebecca Mosig, Brian G Feagan, Fabio Cataldi

J Crohns Colitis· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease.
Séverine Vermeire, Silvio Danese, William J Sandborn, Stefan Schreiber, Stephen Hanauer, Fabio Cataldi

J Crohns Colitis· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE).
Lin Chang, Brooks D Cash, Anthony Lembo, David C Kunkel, Brett A English, Fabio Cataldi

Neurogastroenterol Motil· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
William J Sandborn, Séverine Vermeire, Laurent Peyrin-Biroulet, Marla C Dubinsky, Julian Panes, Fabio Cataldi

Lancet· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiotherapy Screening for Referral of a Patient with Patent Foramen Ovale Presenting with Neck Pain as Primary Complaint: A Case Report.
Giovanni Lopez, Fabio Cataldi, Giuseppe Bellin, James Dunning, César Fernández-de-Las-Peñas

Healthcare (Basel)· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoplastic malignant cord compression mimicking low back pain: A case report.
Fabio Cataldi, Fabrizio Brindisino, Domenico Angilecchia, Alessandro Andreani, Giuseppe Giovannico

Physiother Res Int· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study.
Geert R D'Haens, Walter Reinisch, Scott D Lee, Dino Tarabar, Edouard Louis, Fabio Cataldi

Inflamm Bowel Dis· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing Cranial Nerves in Physical Therapy Practice: Findings from a Cross-Sectional Survey and Implication for Clinical Practice.
Firas Mourad, Giovanni Lopez, Fabio Cataldi, Filippo Maselli, Leonardo Pellicciari

Healthcare (Basel)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II.
Walter Reinisch, William J Sandborn, Silvio Danese, Xavier Hébuterne, Maria Kłopocka, Fabio Cataldi

J Crohns Colitis· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Craniopharyngioma in a young woman with symptoms presenting as mechanical neck pain associated with cervicogenic headache: a case report.
Firas Mourad, Fabio Cataldi, Alberto Patuzzo, Sara Tunnera, James Dunning

Physiother Theory Pract· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hip bone marrow edema presenting as low back pain: a case report.
Firas Mourad, Filippo Maselli, Fabio Cataldi, Denis Pennella, César Fernández-De-Las-Peñas

Physiother Theory Pract· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn's disease in Japanese and Korean patients: the OPERA study.
Masayuki Saruta, Dong Il Park, Young-Ho Kim, Suk-Kyun Yang, Byung-Ik Jang, Fabio Cataldi

Intest Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy Biomarkers.
Huanyu Zhou, Li Xi, Daniel Ziemek, Shawn O'Neil, Julie Lee, Fabio Cataldi

J Crohns Colitis· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II).
Silvio Danese, Séverine Vermeire, Paul Hellstern, Remo Panaccione, Gerhard Rogler, Fabio Cataldi

Gut· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study.
William J Sandborn, Scott D Lee, Dino Tarabar, Edouard Louis, Maria Klopocka, Fabio Cataldi

Gut· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1.
Walter Reinisch, Kenneth Hung, Mina Hassan-Zahraee, Fabio Cataldi

J Crohns Colitis· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study.
Geert D'Haens, Séverine Vermeire, Harald Vogelsang, Matthieu Allez, Pierre Desreumaux, Fabio Cataldi

J Crohns Colitis· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-MAdCAM Antibody Increases ß7+ T Cells and CCR9 Gene Expression in the Peripheral Blood of Patients With Crohn's Disease.
Mina Hassan-Zahraee, Anindita Banerjee, John B Cheng, Weidong Zhang, Alaa Ahmad, Fabio Cataldi

J Crohns Colitis· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Normal intrathecal leukocyte cell number and composition do not decrease the incidence of post-lumbar puncture headache.
Olaf Stüve, Fabio Cataldi, Vivek Pradhan, Kenneth J Gorelick

J Neuroimmunol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
Séverine Vermeire, William J Sandborn, Silvio Danese, Xavier Hébuterne, Bruce A Salzberg, Fabio Cataldi

Lancet· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pharmacokinetic comparison of anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients.
Fei Hua, Jakob Ribbing, Walter Reinisch, Fabio Cataldi, Steven Martin

Br J Clin Pharmacol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.
Walter Reinisch, Julián Panés, Sunil Khurana, Gabor Toth, Fei Hua, Fabio Cataldi

Gut· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target.
Mariangela Allocca, Gionata Fiorino, Severine Vermeire, Walter Reinisch, Fabio Cataldi

Expert Rev Clin Immunol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis